This book includes a plain text version that is designed for high accessibility. To use this version please follow this link.
11-04 :: April/May 2011


nanotimes


Companies Facts


p


Sivida Corp. (NASDAQ: PSDV)(ASX: PVA) announced that its licensee, Alimera Sciences,


Inc., resubmitted a New Drug Application for the investigational drug ILUVIEN®


for the treatment of


diabetic macular edema (DME) to the U.S. Food and Drug Administration (FDA) on May 12, 2011 to address questions raised in the Complete Response Letter (CRL) Alimera received in December 2010. Alimera reported that according to the FDA’s classi- fication scheme, this will be a Class 2 resubmission. Under the Prescription Drug User Fee Act (PDUFA), FDA review of a Class 2 resubmission is expected to be completed within a six-month period beginning on the date that the resubmission is received. http://www.psivida.com


P


VA TePla AG, Wettenberg, a manufacturer of high-temperature vacuum systems and a specia-


list in the construction of crystal-growing systems, is to supply an ion source for plasma (fusion) research to the Max Planck Institute for Plasma Physics in Gar- ching. This ion source is the largest of its kind and, in a major physical experiment, is intended to produce new findings on the generation of high-energy ion beams with large cross-sections for nuclear fusion. This is an important step on the path towards obtai- ning energy in a way that is clean and compatible with mankind and the environment.


In this ion source, a hydrogen gas discharge is gene- rated by irradiation of high frequency. The resultant ions are extracted by high voltage and accelerated through a system of grids towards the test plant. The aim is to optimize the parameters of the ion beam, which in a few years shall be used to heat a fusion plasma up to 80 million degrees Celsius.


Furthermore, the Company has received an order from an Asian solar manufacturer to supply systems for the production of crystalline silicon ingots with an order value over EUR20 million. The order will be processed by the end of 2011/beginning 2012. http://www.pvatepla.com


P


ythagoras Solar, a provider of unprecedented transparent, energy efficient windows that also


generate solar power, has been chosen by Willis Tower, formerly Sears Tower, to collaborate on a pilot project to help deliver on the building‘s re- newable energy and energy efficiency improvement goals.


The pilot project, deployed in November last year on the south facing windows of the Willis Tower‘s 56th floor, uses a building integrated photovoltaic (BIPV) solution that has the potential to expand to a surface area allowing over two megawatts of solar power generation. Willis Tower provides an examp- le of how sustainable modernization endeavors are about more than reducing carbon emissions but also about re-investing in the local economy. Willis Tower is exploring innovative solutions that are directly re-investing in Chicago‘s new green economy. In addition, this project will illustrate one possible best practice for how to decrease the impact of the built environment on climate change, for easy duplication in other similar structures.


Founded in 2007, Pythagoras Solar is uniquely positioned at the intersection of energy efficient building materials and photovoltaics (PV). The company provides building integrated photovoltaic (BIPV) products that enable the architecture, engi- neering and construction sectors to design buildings


43


Page 1  |  Page 2  |  Page 3  |  Page 4  |  Page 5  |  Page 6  |  Page 7  |  Page 8  |  Page 9  |  Page 10  |  Page 11  |  Page 12  |  Page 13  |  Page 14  |  Page 15  |  Page 16  |  Page 17  |  Page 18  |  Page 19  |  Page 20  |  Page 21  |  Page 22  |  Page 23  |  Page 24  |  Page 25  |  Page 26  |  Page 27  |  Page 28  |  Page 29  |  Page 30  |  Page 31  |  Page 32  |  Page 33  |  Page 34  |  Page 35  |  Page 36  |  Page 37  |  Page 38  |  Page 39  |  Page 40  |  Page 41  |  Page 42  |  Page 43  |  Page 44  |  Page 45  |  Page 46  |  Page 47  |  Page 48  |  Page 49  |  Page 50  |  Page 51  |  Page 52  |  Page 53  |  Page 54  |  Page 55  |  Page 56  |  Page 57  |  Page 58  |  Page 59  |  Page 60  |  Page 61  |  Page 62  |  Page 63  |  Page 64  |  Page 65  |  Page 66  |  Page 67  |  Page 68  |  Page 69  |  Page 70  |  Page 71  |  Page 72  |  Page 73  |  Page 74  |  Page 75  |  Page 76  |  Page 77  |  Page 78  |  Page 79  |  Page 80  |  Page 81  |  Page 82  |  Page 83  |  Page 84  |  Page 85  |  Page 86  |  Page 87  |  Page 88  |  Page 89  |  Page 90  |  Page 91  |  Page 92  |  Page 93